REDHILL BIOPHARMA LTD. Cost Of Sales
REDHILL BIOPHARMA LTD. (RDHL) reported Cost Of Sales of $1.61 million for the 6-month period ending 2025-06-30, per its 6-K filed 2025-09-05.
Financial Statements › Expense Statement
ifrs-full:CostOfSales · last filed 2025-09-05
- REDHILL BIOPHARMA LTD. cost of sales for the quarter ending 2022-06-30 was $8.99M, a 15.06% decline year-over-year.
- REDHILL BIOPHARMA LTD. cost of sales for the quarter ending 2021-06-30 was $10.59M, a 25.36% decline year-over-year.
- REDHILL BIOPHARMA LTD. cost of sales for the quarter ending 2020-06-30 was $14.19M, a 3238.35% increase year-over-year.
- REDHILL BIOPHARMA LTD. cost of sales for the quarter ending 2019-06-30 was $425.00K, a 41.38% decline year-over-year.
| Period end | Cost Of Sales 3 month | Cost Of Sales 6 month | Cost Of Sales 12 month |
|---|---|---|---|
| 2025-06-30 | $1.61M 6-K · filed 2025-09-05 | ||
| 2024-12-31 | $3.19M 20-F · filed 2025-04-10 | ||
| 2024-06-30 | $1.40M 6-K · filed 2025-09-05 | ||
| 2023-12-31 | $3.46M 20-F · filed 2025-04-10 | ||
| 2023-06-30 | $2.42M 6-K · filed 2024-08-29 | ||
| 2022-12-31 | $33.34M 20-F · filed 2025-04-10 | ||
| 2022-06-30 | $8.99M 6-K · filed 2022-11-07 | $15.29M 6-K · filed 2023-08-17 | |
| 2021-12-31 | $49.41M 20-F · filed 2024-04-08 | ||
| 2021-06-30 | $10.59M 6-K · filed 2022-11-07 | $20.84M 6-K · filed 2022-11-07 | |
| 2020-12-31 | $36.89M 20-F · filed 2023-04-28 | ||
| 2020-06-30 | $14.19M 6-K · filed 2021-08-26 | $15.90M 6-K · filed 2021-08-26 | |
| 2019-12-31 | $2.26M 20-F · filed 2022-03-17 | ||
| 2019-06-30 | $425.00K 6-K · filed 2020-08-13 | $842.00K 6-K · filed 2020-08-13 | |
| 2018-12-31 | $2.84M 20-F · filed 2021-03-18 | ||
| 2018-06-30 | $725.00K 6-K · filed 2019-07-23 | $1.66M 6-K · filed 2019-07-23 | |
| 2017-12-31 | $2.13M 20-F · filed 2020-03-04 | ||
| 2017-06-30 | $272.00K 6-K · filed 2018-08-30 | $272.00K 6-K · filed 2018-08-30 |